MEDVi Launches Digital-First Weight Loss with GLP-1 Medications

A new telehealth service called MEDVi is offering a digital-first approach to weight-loss treatment in the U.S. The platform connects patients with licensed doctors and compounded GLP-1 medications, aiming to make obesity care more accessible. Traditional weight-loss methods often face hurdles like high costs, long wait times, and limited specialist availability—issues MEDVi seeks to address.

MEDVi's process starts with an online health check-up. Patients then have a virtual consultation with a licensed physician or nurse practitioner to assess whether GLP-1 therapy is medically suitable for them. If approved, prescriptions for compounded drugs like semaglutide or tirzepatide are issued and dispensed by U.S.-licensed pharmacies.

The treatment relies on full patient involvement. Individuals must provide a complete medical history and report any changes in symptoms or side effects during their course. MEDVi stresses that medication alone is not enough—patients are also encouraged to adopt dietary changes, exercise regularly, and maintain ongoing communication with their healthcare team.

By operating entirely online, MEDVi reduces common barriers such as travel, scheduling conflicts, and insurance complications. The service offers cash-pay pricing, which it claims lowers out-of-pocket costs compared to traditional in-person treatments. All medical decisions remain under the supervision of licensed professionals, following state and federal regulations.

MEDVi's model combines telehealth consultations with compounded GLP-1 medications, targeting the growing demand for obesity treatment in the U.S. The service removes some of the usual obstacles by providing remote access to doctors and simplified pricing. Patients, however, must actively participate in their treatment and follow medical guidance for the best results.